Kidney cancer is a cancer that begins in the cells of kidneys. Kidney cancer is a cancer that begins in the kidneys. Kidneys are two bean-shaped organs, each about the size of fist. They're located behind abdominal organs, with one kidney on each side of spine. Renal cell carcinoma (RCC) is one of the most common types of kidney cancer in adults. At the advanced progression stage of kidney cancer, where removal of the cancerous cells is vital, surgical removal of kidney is performed to get cure from the disease. This treatment method has been replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.
Global kidney cancer drugs market is estimated to be valued at US$ 5.83 billion in 2022 and is expected to exhibit a CAGR of 6.4% during the forecast period (2022-2030).
Figure 1. Global Kidney Cancer Drugs Market Share (%), by Pharmacologic Class, 2022
Increased prevalence of renal cell carcinoma is expected to drive the adoption of kidney cancer drugs during the forecast period.
Increasing prevalence of renal cell carcinoma is expected to drive the global kidney cancer drugs market over the forecast period. For instance, in February 2022, American Society of Clinical Oncology (ASCO), in 2022, an estimated 79,000 adults (50,290 men and 28,710 women) in the U.S. would be diagnosed with kidney cancer. Worldwide, an estimated 431,288 people were diagnosed with kidney cancer in 2020. In the U.S., kidney cancer is the sixth most common cancer for men. It is the ninth most common cancer for women. The average age at diagnosis for people with kidney cancer is 64, and most people are diagnosed between the ages of 65 and 74. Renal cell carcinoma (RCC) accounts for approximately 4% of all adult malignancies with nearly 270,000 new cases diagnosed annually worldwide in 2018 according to the National Center for Biotechnology Information.
|Base Year:||2021||Market Size in 2022:||US$ 5.83 Bn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||6.4%||2030 Value Projection:||US$ 9.60 Bn|
Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.
|Restraints & Challenges:||
Figure 2. Global Kidney Cancer Drugs Market Share (%), by Region, 2022
Combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer, which offer lucrative growth opportunities for the market over the forecast period.
In recent times, combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer, which offer lucrative growth opportunities for the market over the forecast period. For instance, in December 2017, the U.S. Food and Drug administration granted Breakthrough Therapy designation to avelumab, PD-L1 immune checkpoint inhibitor, and axitinib, anti-VEGF tyrosine kinase inhibitor (TKI), as a combination therapy for treatment-naive patients with advanced Renal Cell Carcinoma. Furthermore, in January 2018, U.S. Food and Drug administration granted the same designation to, lenvatinib mesylate, multi-TKI, and pembrolizumab, PD-1 immune checkpoint inhibitor, as another combination for mRCC. Moreover, the field of initial treatment therapy for metastatic renal cell carcinoma is moving rapidly towards combination therapy.
Global Kidney Cancer Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a negative impact on the global kidney cancer drugs market, owing to the decrease in research and development activities for kidney cancer drugs. For instance, in May 2020, according to data published by the National Center for Biotechnology Information, the clinicians were focused on developing the SARS-CoV-2 vaccine to prevent the rapid spread of the coronavirus in the world. The coronavirus disease 2019 (COVID-19) was spreading globally at an alarming rate due to which government of countries announced lockdown all over the world. Capacity for surgery has also been reduced as theater space and ventilators have been requisitioned to provide additional critical care capacity for patients with COVID-19. Moreover, anecdotal reports of patients developing COVID-19 after admission to hospital for elective surgery had resulted in patients being more reluctant to have surgery. Thus, as large number of researchers and clinicians were concentrated on developing covid-19 vaccine, the research and development activities for the kidney cancer drugs were decreased.
Global Kidney Cancer Drugs Market: Key Developments
In January 2022, Clinical Hospital of the Faculty of Medicine of Ribeirão Preto collaborated with Bristol Myers Squibb (pharmaceutical company) and São Paulo Research Foundation for developing Nivolumab- new drug on renal cancer. Nivolumab is in the Phase 2 clinical trial whose study was started in January 18 2022. The primary completion date is estimated to be November 30, 2024.
Global Kidney Cancer Drugs Market: Restraint
The major factors that hinder growth of the global kidney cancer drugs market include increasing use of targeted therapies and biologics for treatment of kidney cancer. Targeted therapies are used to control cancer cell when kidney cancer is spread to other organs where chemical drugs are ineffective. Also, targeted therapies for kidney cancer has illustrated higher efficiency than normal chemical drug-based chemotherapy in random clinical trials.
Major players operating in the global kidney cancer drugs market include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.
Kidney cancer or renal carcinoma affects kidney cells to grow out of control and restrict the function of normal cells. Several risk factors associated with kidney cancer include smoking, obesity, workplace exposures substances such as cadmium, some herbicides, and organic solvents, particularly trichloroethylene, high blood pressure, advanced kidney disease, certain medicines, and genetic and hereditary risk factors. Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells that make up clear cell Renal Cell Carcinoma look very pale or clear. Increasing exposure of these risk factors offers lucrative growth outlook in the kidney cancer drugs market, over the forecast period. According to American Cancer Society, January 2018 data findings, kidney cancer was among the 10 most common cancers in the U.S. in both men and women. Men had a higher risk of developing kidney cancer, with about 1 in 48 men and 1 in 83 among women facing lifetime risk of developing kidney cancer. Renal cell carcinoma (RCC) was the most common type of kidney cancer among all types of kidney cancer. In addition, according to same source, around 9 out of 10 kidney cancers were renal cell carcinomas.
Key players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, in January 2019, F. Hoffmann-La Roche Ltd., a healthcare company was working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A), an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion, which would be used as adjuvant treatment in renal cell carcinoma treatment. Tecentriq is in phase III stage.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.